Risk factors for disease progression in HER2-positive breast cancer patients based on the location of metastases

INTRODUCTION: Trastuzumab therapy significantly improves progression-free and overall survival in HER2-positive [HER2(+)] breast cancer (BC) patients. However, in most patients with HER2(+) metastatic BC, the disease progress occurred. The aim of this study was to evaluate the clinicopathological ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Huszno, Joanna, Nowara, Elżbieta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2015
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612553/
https://www.ncbi.nlm.nih.gov/pubmed/26528105
http://dx.doi.org/10.5114/pm.2015.54341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612553/
https://www.ncbi.nlm.nih.gov/pubmed/26528105
http://dx.doi.org/10.5114/pm.2015.54341

Ejemplares similares